Consensus Cogent Biosciences, Inc.

Stocks

COGT

US19240Q2012

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-30 EDT			5-day change	1st Jan Change
31.02 ^USD	-2.94%		-0.61%	-12.67%

09-15	Cogent Biosciences, Inc. Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Advanced Systemic Mastocytosis	CI
09-15	Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application	MT

Evolution of the Average Target: Cogent Biosciences, Inc.

Evolution of the Target Price: Cogent Biosciences, Inc.

Changes in Analyst Recommendations: Cogent Biosciences, Inc.

5fc.YrEFj7elpOBD-XrYhXhe9CPbHlijHjWba-ZZn3sihjY.FYZV7c2U0o0ArC2axhIow3L2dC3bQWWuE9U02jdQ3A9W-m7Jgt_M0BSuIw~fea574a27f4a6d3ad1d3c3f438b00381

Analysts' recommendations: Cogent Biosciences, Inc.

12-08	Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating	MT
11-11	Wedbush Upgrades Cogent Biosciences to Outperform From Neutral, Raises Price Target to $38 From $13	MT
11-10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
25-10-20	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib	CI
25-10-16	Stifel Nicolaus Initiates Coverage on Cogent Biosciences With Hold Rating, $16 Price Target	MT
25-09-03	Raymond James Initiates Cogent Biosciences at Strong Buy	MT
25-08-05	Wedbush Ups Price Target on Cogent Biosciences to $13 From $10, Maintains Neutral Rating	MT
25-07-07	Jefferies Adjusts Price Target on Cogent Biosciences to $28 From $23, Maintains Buy Rating	MT
25-05-06	Wedbush Trims Price Target on Cogent Biosciences to $10 From $11, Maintains Neutral Rating	MT
24-12-11	Needham Downgrades Cogent Biosciences to Hold From Buy	MT
24-09-03	Wedbush Adjusts Cogent Biosciences Price Target to $11 From $10, Maintains Neutral Rating	MT
24-02-26	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT
24-02-26	Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	MT
24-02-23	Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	MT
24-02-08	Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	MT
23-12-15	HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	MT
23-12-11	Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	MT
23-12-08	JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	MT
23-06-08	HC Wainwright Adjusts Price Target on Cogent Biosciences to $27 From $28, Keeps Buy Rating	MT
23-04-28	Baird Initiates Cogent Biosciences at Outperform With $20 Price Target	MT
23-03-15	Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating	MT
23-03-14	Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating	MT
23-01-05	SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating	MT
22-12-14	Needham Starts Cogent Biosciences With Buy Rating, Price Target is $24	MT
22-12-13	Guggenheim Adjusts Price Target on Cogent Biosciences to $24 From $22, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COGENT BIOSCIENCES, INC.					+79.94%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.88%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+34.03%
	Weighted average by Cap.					+27.79%